

1 **Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in**
2 **people living with HIV-1**

3
4 Yanmeng Feng^{1,§}, Yifan Zhang^{2,3,4,§}, Zhangyufan He^{2,4,§}, Haojie Huang⁵, Xiangxiang
5 Tian^{2,3,4}, Gang Wang⁴, Daihong Chen⁴, Yanqin Ren², Liqiu Jia², Wanhai Wang³, Jing
6 Wu², Lingyun Shao², Wenhong Zhang^{2,6,7,8}, Heng Tang^{1,#}, Yanmin Wan^{2,7,9,#}

7
8 ¹ Hubei Provincial Center for Disease Control and Prevention, Wuhan 430065, China;

9 ² Department of Infectious Disease of Huashan Hospital, National Medical Center for
10 Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety
11 Emergency Response, Fudan University, Shanghai 200040, China;

12 ³ Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key
13 Laboratory of Laboratory Medicine of Henan Province, Zhengzhou 450052, China;

14 ⁴ Department of laboratory medicine, Shanghai Public Health Clinical Center, Shanghai
15 201508, China;

16 ⁵ Wuhan Pioneer Social Work Service Center, Wuhan 430071, China;

17 ⁶ Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of
18 Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032,
19 China;

20 ⁷ State Key Laboratory of Genetic Engineering, School of Life Science, Fudan
21 University, Shanghai 200438, China;

22 ⁸ National Clinical Research Centre for Aging & Medicine, Huashan Hospital, Fudan
23 University, Shanghai 200040, China;

24 ⁹ Department of radiology, Shanghai Public Health Clinical Center, Shanghai 201508,
25 China.

26 [§] These authors contribute equally to this work.

27 [#] Correspondence should be addressed to: Heng Tang, 867555881@qq.com; Yanmin
28 Wan, yanmin_wan@fudan.edu.cn

29
30 **Running title:** Evaluating the BIBP-CorV vaccine in PLWH

31 **Word count:** Abstract, 299; main text, 2393

33 **Abstract**

34 **Background** It has been proven that inactivated COVID-19 vaccines are safe and
35 effective in general population with intact immunity. However, their safety and
36 immunogenicity have not been demonstrated in people living with HIV (PLWH).

37 **Methods** 42 HIV-1 infected individuals who were stable on cART and 28 healthy
38 individuals were enrolled in this study. Two doses of an inactivated COVID-19 vaccine
39 (BIBP-CorV) were given 4 weeks apart. The safety and reactogenicity of the vaccine
40 were evaluated by observing clinical adverse events and solicited local and systemic
41 reactions. Humoral responses were measured by anti-spike IgG ELISA and surrogate
42 neutralization assays. Cell-mediated immune responses and vaccine induced T cell
43 activation were measured by flow cytometry.

44 **Findings** All the HIV-1 infected participants had a CD4⁺ T cell count of above 200
45 cells/ μ L both at baseline and 4 weeks after vaccination. No solicited adverse reaction
46 was observed among all participants. Similar binding antibody, neutralizing antibody
47 and S protein specific T cell responses were elicited in PLWH and healthy individuals.
48 Further analyses showed that PLWH with low baseline CD4⁺/CD8⁺ T cell ratios (<0.6)
49 generated lower antibody responses after vaccination than PLWH with medium (0.6~1.0)
50 or high (\geq 1.0) baseline CD4⁺/CD8⁺ T cell ratios ($P < 0.01$). The CD3⁺, CD4⁺ and CD8⁺ T
51 cell counts of PLWH decreased significantly after vaccination, but it did not lead to any
52 adverse clinical manifestation. Moreover, we found that the general burden of HIV-1
53 among the PLWH cohort decreased significantly ($P = 0.0192$) after vaccination. And the
54 alteration of HIV-1 viral load was not significantly associated with the vaccine induced
55 CD4⁺ T cell activation.

56 **Interpretation** Our data demonstrate that the inactivated COVID-19 vaccine is safe and
57 immunogenic in PLWH who are stable on cART with unsuppressed CD4 counts.

58 **Funding** This work was funded by the National Natural Science Foundation of China
59 (Grant No. 81971559, 82041010).

60

61 **Key words:** HIV-1, COVID-19, Inactivated SARS-CoV-2 vaccine, Immunogenicity,
62 Safety

63

64 **Research in context**

65 **Evidence before this study**

66 The safety and efficacy of inactivated COVID-19 vaccines have been validated in
67 general population with intact immunity. However, their safety and immunogenicity have
68 not been demonstrated in people living with HIV (PLWH).

69

70 **Added value of this study**

71 Our study provides the first evidence to show humoral and cellular immune responses
72 to an inactivated vaccine in PLWH who have been stable on cART with good CD4 cell
73 counts. We found that participants with HIV-1 generated antibody and T cell responses
74 comparable with those of healthy individuals after two-dose vaccination. The baseline
75 CD4/CD8 ratios while not the absolute CD4⁺ T cell counts were shown to be associated
76 with the magnitudes of vaccine induced antibody responses. Moreover, we showed that
77 the vaccine induced T cell activation did not increase the viral burden in PLWH on cART.
78 On the contrary, the levels of plasma HIV-1 RNA decreased among a significant
79 percentage of PLWH.

80

81 **Implications of all the available evidence**

82 Our data demonstrate that the inactivated COVID-19 vaccine is safe and immunogenic
83 in PLWH who are stable on cART with unsuppressed CD4 counts and indicate that this
84 vaccine might be protective and efficacious against COVID-19 for people with HIV.

85

86

87

88

89

90

91

92

93

94

95 **Introduction**

96 Even though the well-controlled HIV infection per se is not found as a risk factor of
97 increased SARS-CoV-2 prevalence,^{1,2} it is alerted that the compromised immunities and
98 the high frequencies of comorbidities may render excessive challenges to this
99 population.^{3,4} A more recently released WHO report ([WHO reference number:
100 WHO/2019-nCoV/Clinical/HIV/2021.1](#)) suggests that HIV infection appears to be a
101 significant independent risk factor for both severe/critical COVID-19 presentation at
102 hospital admission and in-hospital mortality. Vaccination against SARS-CoV-2 for
103 PLWH has also been recommended by WHO and health authorities of many countries.
104 However, as a clinical observation showed that SARS-CoV-2 natural infection induced
105 lower protective antibody responses in people with HIV,⁵ it is concerned that the
106 immunogenicity of COVID-19 in PLWH might be weak. The anxiety escalated when the
107 news released from the Novavax COVID-19 vaccine study suggested that HIV infection
108 might dampen the vaccine effectiveness.⁶

109 Reassuringly, more recently published data showed that both the messenger RNA
110 vaccine and the ChAdOx1 nCoV-19 vaccine could elicit protective antibody responses
111 in PLWH comparable with those in healthy individuals.⁷⁻¹⁰ In this study, we compared
112 the antibody responses to two-dose inactivated SARS-CoV-2 vaccination between
113 healthy vaccinees and HIV-1 infected individuals stable on cART. We demonstrated that
114 the inactivated COVID-19 vaccine was immunogenic and safe in PLWH. Baseline
115 CD4⁺/CD8⁺ T cell ratios were found to be associated with both the RBD binding
116 antibody and the neutralizing antibody responses in PLWH.

117

118 **Materials and methods**

119 **Study design and participants**

120 In this open-label two-arm non-randomized study, we enrolled a cohort of HIV-1 infected
121 individuals (n=42) who were stable on cART and under routine follow-up at
122 Hubei Provincial Center for Disease Control and Prevention, China and a cohort of
123 healthy individuals (n=28). Written informed consent was obtained from all participants,
124 and the study was approved by the Research Ethics Committee of Hubei CDC

125 (approval reference number: HBCDC-AF/SC-08/02.0). The demographical
126 characteristics of the enrolled vaccinees were depicted in [Table 1](#).

127

128 **Peripheral lymphocyte count and plasma HIV-1 viral RNA detection**

129 The peripheral lymphocyte counts and plasma HIV-1 viral RNA detections for HIV-1
130 infected individuals were performed using the BD Multitest™ CD3 FITC / CD8 PE /
131 CD45 PerCP / CD4 APC reagent and the COBAS® AmpliPrep / COBAS® TaqMan® HIV-
132 1 Test (v2.0) kit, respectively. All the detections were conducted following the
133 manufacturers` instructions in the clinical laboratory of Shanghai Public Health Clinical
134 Center.

135

136 **Titration of SARS-CoV-2 RBD binding antibody**

137 In-house enzyme-linked immunosorbent assays (ELISA) were developed to measure
138 SARS-CoV-2 RBD specific binding antibodies. High-binding 96-well EIA plates (Cat#
139 9018, Corning, USA) were coated with purified SARS-CoV-2 RBD protein (Cat# 40591-
140 V08H, Sino Biological, China) at a final concentration of 1µg/ml in carbonate/bi-
141 carbonate coating buffer (30mM NaHCO₃, 10mM Na₂CO₃, pH 9.6). Subsequently, the
142 plates were blocked with 1×PBS containing 5% skimmed milk for 1 hour at 37°C. Next,
143 50µl of diluted human plasma was added to each well. After 1-hour incubation at 37°C,
144 the plates were washed with 1×PBS containing 0.05% Tween20 for 5 times. Then, 50µl
145 of an HRP labeled goat anti-human IgG antibody (Cat# ab6759, Abcam, UK) diluted in
146 1×PBS containing 5% skimmed milk were added to each well and incubated for 1 hour
147 at 37°C. After a second round of wash, 50µl of TMB substrate reagent (Cat# MG882,
148 MESGEN, China) was added to each well. 15 minutes later, the color development was
149 stopped by adding 50µl of 1M H₂SO₄ to each well and the values of optical density at
150 OD_{450nm} and OD_{630nm} were measured using 800 TS microplate reader (Cat# 800TS,
151 Biotek, USA).

152

153 **Quantification of SARS-CoV-2 neutralizing antibodies**

154 The neutralizing antibodies against SARS-CoV-2 were detected using a commercialized
155 surrogate neutralization test developed by Suzhou Xinbo Biotechnology Ltd. Company

156 (PerkinElmer, China). The rationale and method of this assay have been elaborated in
157 previous studies.^{11,12} Briefly, plasma samples were firstly incubated with acridinium
158 ester labeled SARS-CoV-2 RBD for 15 min at room temperature. Then, magnetic beads
159 coated with purified human ACE2 protein were added into the mixture and incubated for
160 15 min. After washing, the acridinium ester labeled RBD bound with the magnetic beads
161 were measured by a chemiluminescent reaction. The concentrations of SARS-CoV-2
162 neutralizing antibody correlate negatively with the luminescence intensities, which can
163 be quantified by establishing a standard curve.

164

165 **Flowcytometry assays**

166 To minimize measurement errors, freshly isolated PBMCs were preserved in liquid
167 nitrogen until the last follow-up was completed. Upon recovery, the PBMCs were
168 washed twice with R10 (RPMI1640 with 10% FBS). After counting, 1 million live (trypan
169 blue negative) cells from each sample were added to 96-well round bottom plates and
170 incubated with either R10 or R10 containing synthesized spike protein peptides
171 (0.6µg/ml for each peptide) overnight. Then, the cells were washed and stained
172 sequentially with live/dead dye(Zombie Aqua Fixable Viability Kit, cat#423101,
173 BioLegend), surface marker antibodies (Anti-human-CD3-APC/cyanine 7, cat#300318,
174 BioLegend; anti-human-CD4-BV605, cat#566148, BioLegend; anti-human-CD8-APC,
175 cat#344722, BioLegend; anti-human-HLA-DR-BV421, cat#307636, BioLegend; anti-
176 human-CD38-Percp-Cy5-5, cat#551400, BD Pharmingen) and an intracellular IFN-γ
177 antibody (anti-human-IFN-γ-PE, cat#502509, BioLegend). Stained samples were
178 analyzed using a BD Fortessa flow cytometer and data were analyzed with FlowJo
179 software version 10 (TreeStar Inc., Ashland, OR, USA). The gating strategy is shown in
180 [Supplementary figure 1](#). The evaluation of T cell activation was based on the data
181 generated from wells incubated with R10.

182

183 **Statistical analysis**

184 All the statistical analyses were conducted using Graphpad Prism 9 (GraphPad
185 Software, USA). Normality tests were performed before all downstream statistical
186 analyses except the Chi square test. Comparisons between two groups were performed

187 by the method of *t*-test. Differences among multiple groups were compared by the
188 method of one-way ANOVA. The contingency analysis was done using the method of
189 Chi-square test.

190

191 **Role of the funding source**

192 The funding source was not involved in study design, data collection and analysis, data
193 interpretation, the writing of the report, and the decision to submit the paper for
194 publication.

195

196 **Results**

197 **Baseline characteristics of PLWH and HIV related events after vaccination**

198 In this study, 28 healthy individuals and 42 PLWH were inoculated with two doses of the
199 inactivated vaccine (BIBP-CorV) produced by Beijing Institute of Biological Products on
200 22 April 2021 and 25 May 2021, respectively. PLWH were slightly older than the control
201 (42.74 ± 10.17 versus 37.79 ± 8.804 years, $p=0.0392$). The gender composition and the
202 mean BMI were similar between PLWH and healthy individuals (Table 1). All the HIV-1
203 infected individuals have been on cART since being diagnosed with HIV-1 and have a
204 peripheral CD4⁺ T cell count of >200 cells/ μ L. No solicited adverse reaction was
205 observed among all participants. None of PLWH developed HIV-related clinical events
206 during the study period from 22 April 2021 to 25 June 2021.

207 At the beginning of vaccination, 22 patients had an undetectable plasma viral load, 8
208 patients had detectable viral loads below 20 copies/ml and 12 patients had detectable
209 viral loads beyond 20 copies/ml (Table 2). Unexpectedly, we found that the general viral
210 burden among PLWH decreased after vaccination: 34 patients had an undetectable
211 plasma viral load, 4 patients had detectable viral loads below 20 copies/ml and 4
212 patients had detectable viral loads beyond 20 copies/ml ($P=0.0192$) (Table 2).
213 Meanwhile, our data also showed that the peripheral T cell counts decreased
214 significantly after vaccination, but the CD4⁺/CD8⁺ T cell ratios remained stable (Table 2).

215

216 **The inactivated SARS-CoV-2 vaccine elicited comparable antibody and T cell** 217 **responses in PLWH with those in healthy individuals**

218 To evaluate the immunogenicity of the inactivated SARS-CoV-2 vaccine in our cohorts,
219 peripheral blood samples were collected at baseline, 4 weeks after the first dose and 4
220 weeks after the second dose, respectively. The results of RBD binding antibody assays
221 showed that the inactivated vaccine induced similar levels of RBD binding antibodies in
222 the two cohorts after both the first and the second dose (Fig.1A). We found that the
223 average fold increase of RBD binding antibody was significantly lower in PLWH (Fig.1B),
224 which was presumably due to the relatively high background antibody levels in this
225 cohort (Fig.1A). Neutralizing antibody responses were elicited in most participants after
226 two doses of vaccination (Fig. 1D and 1E) and the magnitudes were similar between
227 PLWH and the healthy control (Fig. 1F). In addition, we also found that the mean levels
228 of S2 binding antibodies were similar between PLWH and healthy individuals both at
229 baseline and 4 weeks post second vaccination (Supplementary Figure 2).
230 The results of flowcytometry assays showed that two-dose inactivated SARS-CoV-2
231 vaccine induced significant T cell responses in both HC and PLWH (Fig.2). Similar
232 magnitudes of S protein specific CD4⁺ (Fig. 2A) and CD8⁺ (Fig. 2B) T cell responses
233 were observed in the two cohorts.

234

235 **Baseline CD4/CD8 ratios were associated with antibody responses after the** 236 **vaccination in the cohort of PLWH**

237 To understand whether the baseline immune status can influence the vaccine induced
238 antibody responses in PLWH, we further analyzed the relationships between baseline T
239 cell counts and post vaccination antibody responses. Our data showed that neither the
240 CD4⁺ T cell counts nor the CD8⁺ T cell counts at baseline correlated with the vaccine
241 induced antibody responses (Data not shown). While, the CD4⁺/CD8⁺ T cell ratios at
242 baseline were found to be associated with antibody responses after the second dose of
243 vaccination (Fig.3). More specifically, the average RBD binding and neutralizing
244 antibody responses of HIV-1 positive vaccinees with low baseline CD4⁺/CD8⁺ T cell
245 ratios (<0.6) were significantly lower than those with medium (0.6-1.0) or high (≥1.0)
246 baseline CD4⁺/CD8⁺ T cell ratios (Fig.3A and 3B). Slightly different from the RBD
247 binding antibody and the nAb responses, we observed that S2 binding antibody
248 responses in HIV-1 positive vaccinees with medium baseline CD4⁺/CD8⁺ T cell ratios

249 were significantly higher than those with both low and high baseline CD4⁺/CD8⁺ T cell
250 ratios (Fig.3C). We also analyzed the impacts of baseline CD4⁺/CD8⁺ T cell ratios on T
251 cell responses and found that there was no significant difference among PLWH with low,
252 medium and high baseline CD4⁺/CD8⁺ T cell ratios (Supplementary figure 3).

253

254 **The patterns of vaccine induced T cell activation were different between HC and** 255 **PLWH**

256 Vaccine induced activation of T cells was considered as a major constraint that might
257 compromise vaccine conferred benefits in PLWH.¹³⁻¹⁵ To investigate whether the
258 vaccine induced T cell activation was associated with the observed fluctuation of HIV-1
259 viral load, we measured the expressions of CD38 and HLA-DR on CD4⁺ and CD8⁺ T
260 cells by flowcytometry. We observed that the patterns of vaccine induced T cell
261 activation were different between HC and PLWH (Fig.4). Of note, our data showed that
262 the percentages of CD38⁺HLA-DR⁻ CD4⁺ T cells (Fig.4B) increased, while the
263 percentages of CD38⁻HLA-DR⁺ CD8⁺ T cells (Fig.4D) decreased in PLWH after
264 vaccination. The decrease of CD38⁻HLA-DR⁺CD8⁺ T cells has been reported by a
265 previous study,¹³ however, the underlying mechanism is not clear. We further analyzed
266 the association between the observed T cell activation and plasma viral load fluctuation.
267 Although no statistical significance was reached, our results showed that the vaccine
268 induced fold-changes of CD38⁺HLA-DR⁻, CD38⁻HLA-DR⁺ and CD38⁺HLA-DR⁺CD4⁺ T
269 cells tended to be higher in viral increased PLWH (Supplementary figure 4).

270

271 **Discussion**

272 Even if the replication of HIV is controlled by cART, it can still be harder for PLWH to
273 defend against infectious diseases.¹⁶ Therefore, vaccination is recommended for PLWH
274 whose peripheral CD4⁺ T cell counts are more than 200 cells/ μ L.¹⁷ However, due to the
275 compromised immune status, the vaccine elicited immune responses might be impaired
276 in PLWH.¹⁸⁻²¹ The efficacies of COVID-19 vaccines in PLWH were also seriously
277 concerned, because it has been suggested that HIV-1 infection could alter the host
278 immune responses against SARS-CoV-2.²² Here, we provided evidence showing that
279 an inactivated SARS-CoV-2 vaccine (BIBP-CorV) was immunogenic and safe in PLWH.

280 Importantly, our data demonstrated that the inactivated vaccine induced comparable
281 antibody and T cell responses between PLWH and HC.

282 All the HIV-1 positive participants in our cohort had a CD4⁺ T cell count of >200 cells/ μ L
283 both at baseline and 4 weeks post vaccination. We found a statistically significant
284 decrease in CD4⁺ T cell count between the baseline levels and those measured
285 following the second vaccination. The decrease of CD4⁺ T cell count after vaccination
286 had also been observed in PLWH inoculated with the BNT162b2 mRNA vaccine and
287 several other vaccines usually recommended for PLWH.^{23,24} Increases in activated T
288 cells were found to be associated with decreases in CD4⁺ T cell count among PLWH
289 received vaccination,²⁴ but the reason is still not clear. Of note, both our and other
290 studies did not identify any adverse clinical manifestation that was associated with the
291 drop of CD4⁺ T cell count.^{23,24} Stable cART might be crucial to counteract the potential
292 vaccine related deleterious effect in PLWH according to a recently published case
293 report, which observed viral activation and CD4⁺ T cell loss in a treatment-naïve HIV-
294 positive patient after receiving two doses of inactivated COVID-19 vaccines.²⁵

295 Quite surprisingly, we observed a significant drop of general viral burden in the PLWH
296 cohort after vaccination. As percentages of activated T cells may correlate with HIV-1
297 replication, we further evaluated the vaccine induced T cell activation by measuring the
298 expressions of CD38 and HLA-DR on T cells. We found that the percentages of
299 CD38⁺HLA-DR⁻CD4⁺ T cells and CD38⁺HLA-DR⁺CD4⁺ T cells increased significantly
300 after vaccination. We speculate that the elimination of activated HIV-1 infected CD4⁺ T
301 cells by cART or autologous CTLs might account for the observed drop of HIV burden in
302 the PLWH cohort.

303 Despite the generally comparable antibody responses between PLWH and healthy
304 individuals, we demonstrated that HIV-1 infected vaccinees with low baseline
305 CD4⁺/CD8⁺ T cell ratio (<0.6) generated weaker antibody responses after vaccination,
306 which was in line with previous reports showing that CD4⁺/CD8⁺ T cell ratios could
307 predict vaccine induced antibody responses in HIV-1 infected patients and HIV
308 negative elderly.^{26,27} Additionally, we showed that the baseline CD4⁺/CD8⁺ T cell ratios
309 did not impact the induction of specific T cell responses. Given that most vaccine
310 induced antibody responses are CD4⁺ T cell dependent, a potential explanation for the

311 above phenomena is that the low CD4⁺/CD8⁺ T cell ratio might reflect the suboptimal
312 support for antibody responses.

313 A major limitation of this study is the inadequate follow-up, which do not allow us to
314 compare the persistence of antibody responses between PLWH and the healthy control.
315 Despite of this limitation, our study demonstrates that the inactivated COVID-19 vaccine
316 was immunogenic and safe in PLWH stable on cART.

317

318 **Declaration of interests**

319 The authors declare no conflict of interest.

320

321 **Author contributions**

322 YW and HT were involved in the study design and supervision; YF, YZ, ZH, XT
323 GW, DC and LJ were involved in data collection; YR, WW, JW, LS, WZ and YW
324 performed the data analysis; YW, YF and HT drafted the manuscript; WZ, LS, YW and
325 HT revised the manuscript. HH coordinated the enrollment of PLWH. The underlying
326 data have been verified by YF and YW.

327

328 **Data sharing**

329 Anonymized participant-level data will be made available 3 months following publication,
330 upon requests directed to the corresponding author. After being approved by the
331 sponsors (Fudan University and Hubei provincial CDC) and investigators
332 , the data can be shared through a secure online platform. All data will be made
333 available for a minimum of 5 years after publication.

334

335 **Acknowledgments**

336 We thank Dr. Lianguo Ruan from Wuhan Jinyintan Hospital for his help in PLWH cohort
337 enrollment. We thank the volunteers who participated in this study. This work was
338 funded by the National Natural Science Foundation of China (Grant No. 81971559,
339 82041010).

340

341 **References**

342 1. Kanwugu ON, Adadi P. HIV/SARS-CoV-2 coinfection: A global perspective. *Journal of medical virology*
343 2021; **93**(2): 726-32.

344 2. Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in adults living with
345 HIV. *The lancet HIV* 2021; **8**(5): e294-e305.

346 3. Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 Among People Living with HIV: A
347 Systematic Review. *AIDS and Behavior* 2021; **25**(1): 85-92.

348 4. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in
349 HIV/AIDS patients: a systematic review. *HIV medicine* 2020; **21**(9): 567-77.

350 5. Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus
351 neutralising antibody titres after infection, compared by HIV status: a matched case-control
352 observational study. *The lancet HIV* 2021; **8**(6): e334-e41.

353 6. Callaway E, Mallapaty S. Novavax offers first evidence that COVID vaccines protect people against
354 variants. *Nature* 2021; **590**(7844): 17.

355 7. Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA Vaccine Elicits Robust Humoral
356 and Cellular Immune Responses in People Living with HIV. *Clinical infectious diseases : an official*
357 *publication of the Infectious Diseases Society of America* 2021.

358 8. Ruddy JA, Boyarsky BJ, Bailey JR, et al. Safety and antibody response to two-dose SARS-CoV-2
359 messenger RNA vaccination in persons with HIV. *AIDS (London, England)* 2021.

360 9. Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222)
361 vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *The*
362 *lancet HIV* 2021; **8**(8): e474-e85.

363 10. Spinelli MA. SARS-CoV-2 vaccination in people with HIV. *The lancet HIV* 2021; **8**(8): e455-e6.

364 11. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat*
365 *Commun* 2021; **12**(1): 63.

366 12. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist
367 for months. *Science (New York, NY)* 2020; **370**(6521): 1227-30.

368 13. Onlamoon N, Unpol P, Boonchan M, et al. Immune activation and viral replication after vaccination
369 with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy. *Disease*
370 *markers* 2013; **35**(4): 221-7.

371 14. Hu H, Eller MA, Zafar S, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5
372 naturally exposed and recombinant Ad5-HIV vaccinated individuals. 2014; **111**(37): 13439-44.

373 15. Immunization with Both T Cell-Dependent and T Cell-Independent Vaccines Augments HIV Viral Load
374 Secondarily to Stimulation of Tumor Necrosis Factor α . 1998; **14**(9): 727-34.

375 16. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. *AIDS patient care and STDs* 2014;
376 **28**(8): 397-410.

377 17. Frésard A, Gagneux-Brunon A, Lucht F, Botelho-Nevers E, Launay O. Immunization of HIV-infected
378 adult patients - French recommendations. *Human vaccines & immunotherapeutics* 2016; **12**(11): 2729-
379 41.

380 18. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients:
381 systematic review and meta-analysis from a public health policy perspective. *PloS one* 2011; **6**(12):
382 e29249.

383 19. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled
384 HIV-infected individuals. *AIDS (London, England)* 2010; **24**(14): 2187-92.

385 20. George VK, Pallikkuth S, Parmigiani A, et al. HIV infection Worsens Age-Associated Defects in
386 Antibody Responses to Influenza Vaccine. *The Journal of infectious diseases* 2015; **211**(12): 1959-68.

387 21. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 Infection in Infants Severely Impairs the Immune
388 Response Induced by Bacille Calmette-Guérin Vaccine. *The Journal of infectious diseases* 2009; **199**(7):
389 982-90.

390 22. Karim F, Gazy I, Cele S, et al. HIV infection alters SARS-CoV-2 responsive immune parameters but not
391 clinical outcomes in COVID-19 disease. 2020: 2020.11.23.20236828.
392 23. Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA
393 Covid-19 vaccine in people living with HIV-1. *Clinical microbiology and infection : the official publication*
394 *of the European Society of Clinical Microbiology and Infectious Diseases* 2021.
395 24. Castro P, Plana M, González R, et al. Influence of a vaccination schedule on viral load rebound and
396 immune responses in successfully treated HIV-infected patients. *AIDS research and human retroviruses*
397 2009; **25**(12): 1249-59.
398 25. Gong C, Song X, Li X, Lu L, Li T. Immunological Changes after COVID-19 Vaccination in an HIV-Positive
399 Patient. *International journal of infectious diseases : IJID : official publication of the International Society*
400 *for Infectious Diseases* 2021.
401 26. Avelino-Silva VI, Miyaji KT, Hunt PW, et al. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine
402 Immunogenicity in HIV-Infected Patients. *PLoS neglected tropical diseases* 2016; **10**(12): e0005219.
403 27. Strindhall J, Ernerudh J, Mörner A, et al. Humoral response to influenza vaccination in relation to pre-
404 vaccination antibody titres, vaccination history, cytomegalovirus serostatus and CD4/CD8 ratio.
405 *Infectious diseases (London, England)* 2016; **48**(6): 436-42.

406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427

428 **Figure legends**

429

430 **Figure 1 The inactivated SARS-CoV-2 vaccine elicited comparable RBD binding**
431 **antibody and neutralizing antibody responses in PLWH with those in the control**

432 All participants in our study received two doses of the inactivated SARS-CoV-2 vaccine
433 (BIBP-CorV) produced by Beijing Institute of Biological Products at an interval of 4
434 weeks. Peripheral blood samples were collected at baseline, 4 weeks post the 1st dose
435 and 4 weeks post the 2nd dose. RBD binding antibody (**A, B, C**) and neutralizing
436 antibody (**D, E, F**) responses were measured and compared between PLWH (n=28) and
437 healthy individuals (n=42). Statistical analyses were performed by the method of non-
438 parametric t test. ****, P<0.0001.

439

440 **Figure 2 Comparisons of S protein specific T cell responses between PLWH and** 441 **healthy individuals**

442 S protein specific IFN- γ secreting T cells were measured using flowcytometry. The
443 inactivated vaccine elicited similar levels of S protein specific CD4⁺ (**A**) and CD8⁺ T cell
444 responses (**B**) in PLWH and HC. Statistical analyses were performed by the method of
445 non-parametric t test. ****, P<0.0001.

446

447 **Figure 3 Baseline CD4⁺/CD8⁺ T cell ratios were associated with specific antibody** 448 **responses after vaccination in PLWH**

449 HIV-1 infected participants were stratified into 3 subgroups according to their baseline
450 CD4⁺/CD8⁺ T cell ratios (<0.6, 0.6~1.0 and \geq 1.0). RBD binding antibody (**A**),
451 neutralizing antibody (**B**) and S2 binding antibody (**C**) responses were compared among
452 the three subgroups. Statistical analysis for (**A**) was performed by the method of non-
453 parametric t test and statistical analyses for (**B**) and (**C**) were done by the method of
454 parametric t test. *, P<0.05; **, P<0.01; ***, P<0.001.

455

456 **Figure 4 The patterns of vaccine induced T cell activation were different between** 457 **PLWH and HC**

458 The activation of T cells was assessed through detecting the expressions of CD38 and
459 HLA-DR on T cells. (**A, B, C**) The percentages of CD38⁻HLA-DR⁺, CD38⁺HLA-DR⁻ and
460 CD38⁺HLA-DR⁺ among CD4⁺ T cells. (**D, E, F**) The percentages of CD38⁻HLA-DR⁺,
461 CD38⁺HLA-DR⁻ and CD38⁺HLA-DR⁺ among CD8⁺ T cells. Statistical analyses were
462 performed by the method of two-way ANOVA. **, P<0.01; ****, P<0.0001.

463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487

Table 1 Demographical characteristics of enrolled vaccinees

	PLWH	HC	P value
Gender			
Man (n)	29	16	0.3228
Woman (n)	13	12	
Age (Year, mean±SD)	42.74±10.17	37.79±8.804	0.0392
BMI (Mean±SD)	23.97±6.967	24.07±3.8	0.2867

Note: PLWH, people living with HIV; HC, healthy control

Table 2 Peripheral T cell counts and plasma viral loads of PLWH

	Baseline	4 weeks post the 2nd dose	P value
T cell count			
(Mean ± SD cells/μL, n)			
CD3 ⁺ T	1550 ± 502, 28	1121 ± 336, 28	Paired t-test, <0.0001
CD4 ⁺ T	659 ± 222, 28	477 ± 151, 28	Paired t-test, <0.0001
CD8 ⁺ T	813 ± 361, 28	586 ± 240, 28	Paired t-test, <0.0001
CD4⁺ T/CD8⁺ T ratio			
(Median, 25%-75% percentile, n)	0.86, 0.60-1.05, 28	0.82, 0.62-1.25, 28	Paired rank test, 0.5194
Plasma viral load			
>20 copies/mL (n)	12	4	
<20 copies/mL (n)	8	4	Chi square test, 0.0192
Undetectable (n)	22	34	

Figure 1 Comparisons of RBD binding antibody and neutralizing antibody responses between PLWH and healthy individuals





Figure 2 Comparisons of S specific T cell responses between PLWH and healthy individuals

A



B




Figure 3 Baseline CD4/CD8 ratios were associated with the antibody responses after two doses of vaccination in PLWH




Figure 4 The patterns of vaccine induced T cell activation were different between PLWH and HC

